FDA Announces Joint Meeting of Psychopharmacologic Drugs and Drug Safety Advisory Committees

Summary

The US Food and Drug Administration (FDA) is hosting a joint meeting of its Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, inviting public input and comments on regulatory issues